Date: 2017-04-05
Type of information: Licensing agreement
Compound: FIN-524
Company: Takeda Pharmaceutical (Japan) Finch Therapeutics (USA - MA)
Therapeutic area:
Type agreement: licensing - development - commercialisation
Action mechanism:
- microbiome therapeutic. FIN-524 is a live biotherapeutic product in pre-clinical research. It is composed of cultured bacterial strains that have been linked to favorable clinical outcomes in studies of microbiota transplantations in inflammatory bowel disease.
- FIN-524 is Finch’s first product candidate based on a synthetic ecology of microorganisms. Finch Therapeutics is a microbiome engineering company that has been founded by data scientists, clinicians, and microbiologists from MIT and OpenBiome. Finch uses machine learning algorithms informed by high-throughput molecular data to reverse engineer successful experiences with fecal transplantation. Rather than relying on in-vitro screening of a library of isolates, Finch uses this human-first discovery approach to identify strains that drive clinical phenotypes of interest and to develop therapies that deliver these microbial communities to patients.
Disease: inflammatory bowel disease
Details:
- • On April 5 2017, Finch Therapeutics and Takeda Pharmaceutical announced a global collaboration agreement to jointly develop FIN-524 in inflammatory bowel disease. The collaboration combines Finch’s unique discovery platform with Takeda’s strength in drug development for gastrointestinal diseases to advance a new class of microbial therapy.
- Finch and Takeda may elect to extend this collaboration to additional, related indications on similar terms. Further details of the agreement were not disclosed.
Financial terms:
- Under the terms of the agreement, Takeda will make an upfront payment of $10 million to Finch for the exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in in inflammatory bowel disease. Finch will be eligible for development, regulatory and commercial financial milestones and tiered royalties on worldwide net sales.
Latest news:
Is general: Yes
